Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) but is challenging after treatment failure. Appropriate criteria for enrolling patients into second-line trials are still limited. In this study, we aimed to establish more objective criteria based on Albumin-Bilirubin (ALBI) grade to select patients with better post-progression survival (PPS) for second-line treatment.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Liver Int.

Title: Liver international : official journal of the International Association for the Study of the Liver

Publisher: Wiley

ISSN (Electronic): 1478-3231

ISSN (Print): 1478-3223

Publication date (Electronic): February 2018

Volume: 38

Issue: 2

Affiliations

[1 ] Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

[2 ] Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

[3 ] Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

[4 ] Department of Nursing, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

[5 ] Cancer Center, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

[6 ] Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

Article

DOI: 10.1111/liv.13527

PubMed ID: 28736952

SO-VID: f6f1099e-2c90-4713-8d23-e8808e7c86ea

History

Keywords: advanced hepatocellular carcinoma,ALBI-PD criteria,post-sorafenib second-line treatment,new extrahepatic metastasis

Data availability:

Keywords: advanced hepatocellular carcinoma, ALBI-PD criteria, post-sorafenib second-line treatment, new extrahepatic metastasis

Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.

Read this article at

Abstract

Related collections

Recursive Rule based Visual Categorization

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 149

Cited by 23